Stocktoria
TriSalus Life Sciences, Inc. TLSI
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-12-18
TriSalus Life Sciences, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | $12.4M | — |
| Gross profit | $38.2M | $25.3M | $15.9M | $10.1M | — |
| R&D expense | $15.0M | $17.7M | $29.8M | $21.4M | — |
| Operating income | -$26.9M | -$36.2M | -$54.5M | -$36.4M | -$3.0M |
| Interest expense | — | — | $16,000 | $1,000 | — |
| Income tax | $7,000 | $6,000 | $9,000 | $9,000 | $0 |
| Net income | -$39.2M | -$30.0M | -$59.4M | -$47.2M | $4.8M |
| EPS (diluted) | $-1.84 | $-1.31 | $-6.77 | $-161.55 | — |
| Operating cash flow | -$18.0M | -$40.8M | -$50.6M | -$32.3M | -$1.7M |
| Free cash flow | -$18.9M | -$41.2M | -$51.2M | -$33.0M | — |
| Cash & equivalents | $20.4M | $8.5M | $11.8M | $9.4M | $200,884 |
| Inventory | $3.1M | $4.0M | $2.5M | $1.5M | — |
| Total assets | $35.3M | $24.0M | $24.6M | $22.0M | $250.5M |
| Total liabilities | $69.2M | $49.9M | $51.7M | $34.3M | $17.3M |
| Shareholders' equity | -$33.9M | -$25.9M | -$27.1M | -$177.1M | -$129.6M |
Growth · year-over-year · Revenue CAGR 53.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | +53.4% | +59.0% | +49.3% | — | — |
| Net income growth | — | — | — | -1089.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.